申请人:Sumitomo Pharmaceuticals Company, Limited
公开号:EP1340756A1
公开(公告)日:2003-09-03
1. A β-lactam compound of the formula [1];
wherein R1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y2 is hydrogen, an alkyl, cyano, -C(R3)=NR4 (wherein R3 and R4 are hydrogen, an amino, an alkyl, etc., or R3 and R4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.
1.一种式[1]的β-内酰胺化合物;
其中 R1 是低级烷基、被羟基取代的低级烷基;R2 是氢、低级烷基;X 是 O、S、NH;m 和 n 是 0 至 4;Y1 是卤素、氰基、羟基、氨基、低级烷氧基、低级烷氨基、羧基、氨基甲酰基、低级烷基等;Y2 是氢、烷基、氰基、-C(R3)=NR4(其中 R3 和 R4 是氢、氨基、烷基等、或 R3 和 R4 可与氮原子相互结合形成 5 至 7 元杂环基团),或其药学上可接受的盐,或其无毒酯,对革兰氏阳性菌,尤其是 MRSA 和 MRCNS 具有优异的抗菌活性。